Search
Oncotype DX for prostate cancer
Indications:
- assessment of prostate carcinoma
Contraindications:
- not appropriate for carcinoma in situ
- not appropriate for metastatic cancer
Procedure:
- analyzes 17 genes, presumably expression of 17 genes
Specimen:
- tissue from prostate biopsy
Notes:
- introduced in 2013
- price (2012) $3800
Related
prostate cancer
General
Oncotype DX
References
- Physician's First Watch, May 9, 2013
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- Pollack A
New Test Improves Assessment of Prostate Cancer Risk, Study Says.
New York Times, May 8, 2013
http://www.nytimes.com/2013/05/08/business/prostate-cancer-test-from-genomic-health-assesses-risks.html?_r=0
- Marchione M
Gene test may help guide prostate cancer treatment.
Associated Press. May 8, 2013
http://health.usnews.com/health-news/news/articles/2013/05/08/gene-test-may-help-guide-prostate-cancer-treatment2) Mulcahy N
'Notable Differences' With 3 Prostate Cancer Genomics Tests.
Medscape - May 20, 2018.
https://www.medscape.com/viewarticle/896937